Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting

Clinical trial NCT04828057 · COMPLETED

Trial details

NCT number: NCT04828057
Sponsor: Santen Pharmaceutical (Taiwan) Co., LTD
Status: COMPLETED
Study type: OBSERVATIONAL

Ocular Surface Disease Primary Open Angle Glaucoma

Start date: 2021-09-01
Primary completion: 2022-08-24
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.